Trials in Progress Poster Session: Colorectal Cancer

Go to 17 Presentations

Choice of two posters:

Arvind Dasari, James C. Yao, Alberto F. Sobrero, et al.

Authors conclusion: Final OS analyses will be performed when 364 OS events are observed; futility analysis will be conducted with 1/3 (121) OS events. If enrichment of post-regorafenib pts occurs, enrollment to that strata will be capped at approximately 262. FRESCO-2 will be activated in the US, EU, and Japan; global enrollment is anticipated over 13 mo.

 

Farshid Dayyani, Kit Tam, Edward Kim, et al.

Authors conclusion: Primary objective: Feasibility of the regimen and estimate of efficacy. Primary endpoint: PFS6. Secondary objectives: OS, ORR, adverse events. Total number of pts to be enrolled N=20. Current enrollment (September 2020) N=14. Clinical trial information: NCT04074343